Treatment of inflammatory bowel disease

Details Treatment of inflammatory bowel disease Treatment of inflammatory bowel disease

2011-03-29

2011-03-29

Sheikh, Humera N (Department: 1615)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Tablets, lozenges, or pills

C424S468000, C424S474000

Reexamination Certificate

active

07914817

ABSTRACT:
Patients suffering from inflammatory bowel disease such as Crohn's disease or ulcerative colitis are treated either orally or intravenously with methylol transfer agents, such as taurolidine and/or taurultam. These agents can be used in combination with other drugs thereby allowing the use of smaller amounts of the other drugs and limiting unwanted side effects.

REFERENCES:
patent: 3423408 (1969-01-01), Pfirrmann
patent: 4022889 (1977-05-01), Bannister
patent: 4096241 (1978-06-01), Geistlich et al.
patent: 4107305 (1978-08-01), Pfirrmann
patent: 4337251 (1982-06-01), Pfirrmann
patent: 4587268 (1986-05-01), Pfirrmann
patent: 4604391 (1986-08-01), Pfirrmann
patent: 4626536 (1986-12-01), Pfirrmann
patent: 4772468 (1988-09-01), Pfirrmann
patent: 4882149 (1989-11-01), Spector
patent: 4960415 (1990-10-01), Reinmüller
patent: 5077281 (1991-12-01), Reinmuller
patent: 5187082 (1993-02-01), Hamill et al.
patent: 5210083 (1993-05-01), Pfirrmann
patent: 5256684 (1993-10-01), Marshall
patent: 5304540 (1994-04-01), Blackburn et al.
patent: 5316774 (1994-05-01), Eury et al.
patent: 5417975 (1995-05-01), Lussi et al.
patent: 5559096 (1996-09-01), Edwards et al.
patent: 5591714 (1997-01-01), Nagarajan et al.
patent: 5593665 (1997-01-01), Pfirrmann
patent: 5599794 (1997-02-01), Eek et al.
patent: 5650320 (1997-07-01), Caufield et al.
patent: 5972933 (1999-10-01), Pfirrmann
patent: 6251896 (2001-06-01), Costin
patent: WO 90/06138 (1990-06-01), None
patent: WO 91/04732 (1991-04-01), None
patent: WO 91/13628 (1991-09-01), None
patent: 9725980 (1997-07-01), None
patent: WO 97/25980 (1997-07-01), None
patent: WO 97/27843 (1997-08-01), None
“5-ASA (mesalamine) oral medications”, MedicineNet.com, Nov. 24, 2008, 5 pages.
“Ibuprofen”, Wikipedia.org, Nov. 24, 2008, 8 pages.
Drygalski, et al., “Vancomycin-Induced Immune Thrombocytopenia”, The New England Journal of Medicine, vol. 356:904-910, Mar. 1, 2007, No. 9, 10 pages.
“Vancomycin”, Drugs.com, Dec. 3, 2008, 3 pages.
Pravda, “Radical induction theory of ulcerative colitis”, World Journal of Gastroenterology, vol. 11, No. 16, Apr. 28, 2005, ISSN 1007-9327, pp. 2371-2384.
Dickinson, et al., “Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis”, Gut, 1985; 26, pp. 1380-1384.
Chapman, et al., “Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis”, Gut, 1986:27, pp. 1210-1212.
Gardiner, K.R. et al., “Enteral and Parenteral Anti-Endotoxin Treatment in Experimental Colitis” Hepato-Gastroenterology, vol. 41, No. 6, 1994, pp. 554-558, Northern Ireland.
Johnston, D.A. et al., “Taurolin for the prevention of parenteral nutrition related infection: antimicrobial activity and long-term use” Clinical Nutrition, vol. 12, No. 6, Dec. 1, 1993, pp. 365-368, London, England.
Baert, F.J. et al., “Anti-TNF strategies in Crohn's disease: mechanisms, clinical effects, indications” Int'l. Journal of Colorectal Disease, vol. 14, No. 1, Feb. 1999, pp. 47-51, Berlin, Germany.
J.A.F. Reynolds Editor, “Martindale—The Extra Pharmacopoeia—30th Ed.” 1993, The Pharmaceutical Press, p. 211, middle column, paragraph 2, London, England.
Vincent, Jean-Louis, “Dear SIRS, I'm sorry to say that I don't like you . . . ”,Crit. Care Med., 1997, vol. 25, No. 2, pp. 372-374.
Bone, R.C., “Sepsis and Septic Shock”, Consultant Series (3) No. 2, pp. 1-3 and 5-25 (1987).
Stinson, S., “Drug Firms Restock Antibacterial Arsenal”,Product Report, Sep. 23, 1996, C&EN.
Rampp, U., “Medizin Im Dialog”, Aug. 1996 (untranslated), pp. 1-27.
Traub, W. et al., “Enterococcus faecium: In vitro Activity of Antimicrobial Drugs, Singly and Combined, with and without Defibrinated Human Blood, against Multiple-Antibiotic-Resistant Strains”,Chemotherapy, 1993, vol. 39, pp. 254-264.
Browne, M.K. et al., “The in Vitro and in Vivo Activity of Taurolin Against Anaerobic Pathogenic Organisms”,Surgery, Gynecology&Obstetrics, 1977, vol. 145, pp. 842-846.
Willatts, S. et al., “Effect of the Antiendotoxic Agent, Taurolidine, in the Treatment of Sepsis Syndrome: A Placebo-Controlled Double-Blind Trial”,Critical Care Med., 1995, vol. 23, No. 6, pp. 1033-1039.
Jones, D.S. et al., The Effects of Three Non-Antibiotic, Antimicrobial Agents on the Surface Hydrophobicity of Certain Micro-Organisms Evaluated by Different Methods,J. Appl. Bacteriol., 1991, vol. 71, pp. 218-227.
Hancock, R., “Peptide Antibiotics”,The Lancet, 1997, vol. 349, pp. 418-422.
Zimmerman, M. et al., “In Vitro Activity of Taurolidine, Chlorophenol-Camphor-Menthol and Chlorhexidine Against Oral Pathogenic Microorganisms”,Arzneim-Forsch/Drug Res., 1992, vol. 42(II), pp. 1157-1159.
Focht, J. et al., “Spectrum of Pathogens and Resistance in Peritonitis”,Langebecks Arch Chir., 1997, vol. 382 (suppl 1), S1-S4.
Vankemmel, M. et al., “Traitement Anti-Infectieux Local et General Par Utilisation D'un Nouvel Antiseptique en Chirurgie Bilio-Pancreatique: Un Defi Ax Antibiotiques?”,Med Interne, 1979, vol. 14, No. 12, pp. 683-688 (untranslated).
Ruegsegger, C.H. et al., “Tauroline in Intra-Abdominal Infections”,Helv. Chir. Acta., 1978, vol. 45, No. 6, pp. 743-747 (untranslated).
Ruegsegger, C.H. et al., “Comparative Study on Prophylactic Antibiotics Versus Perioperative Taurolidine in Colonic Surgery”,Helv. Chir. Acta., 1983, vol. 50, pp. 117-120 (untranslated).
Rosman, C., et al., “Effect of Intraperitonial Antimicrobials on the Concentration of Bacteria, Endotoxin, and Tumor Necrosis Factor in Abdominal Fluid and Plasma in Rats”,Eur. Surg. Res., 1996, vol. 28, No. 5, pp. 351-360.
Gortz, G., “Local Antiseptic and Antiendotoxic Measures in the case of Intraabdominal Infections”,Langenbecks Archiv Für Chirurgie, 1997, vol. 382 (Suppl 1), S.37-S41.
Linder, M. et al., “Therapy of Purulent Peritonitis”,Langenbecks, Arch Chir., 1981, vol. 353, No. 4, pp. 241-250.
Brown, M, The Treatment of Peritonitis by an Antiseptic—Tauroline,Pharmatherapeutica, 1981, vol. 2, No. 8, pp. 517-522.
Traub, Wh. et al., “Taurolidine: In Vitro Activity Against Multiple-Antibiotic-Resistant, Nosocomially Significant Clinical Isolates of Staphylococcus Aureus, Enterococcus Faecium, and Diverse Enterobacteriaceae”,Chemotherapy, 1993, vol. 39 (5).
Tarao, M. et al., “Effect of Paromomycin Sulfate on Endotoxemia in Patients with Cirrhosis”,J. Clin Gastroenterol, 1982, vol. 4 (3).
Krawzak, H.W., et al., “Taurolinein the Local Treatment of Peritonitis”,Aktuel. Chir., 1987, Abstract.
Reith, HB, et al., “Peritonitis Therapy Today: Surgical Management and Adjuvant Medical Therapies”,Langenbecks Archiv. Fur Chirurgie, 1997, vol. 382 (4 Suppl. 1), Abstract.
Lai, K et al., “35thInterscience Conference on Antimicrobial Agents and Chemotherapy”,Abstracts of the 35thICAAC, Abstract (1995 ).

Affiliated with

Also associated with

Rating

Treatment of inflammatory bowel disease does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of inflammatory bowel disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of inflammatory bowel disease will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2621405